1. A real-life comparison of pulmonary and nasal outcomes in patients with severe asthma and nasal polyposis treated with T2-biologics
- Author
-
Ulrike Förster-Ruhrmann, MD, Dafni Stergioudi, MD, Agnieszka J. Szczepek, PhD, Joachim W. Fluhr, MD, PhD, Torsten Zuberbier, MD, PhD, Heidi Olze, MD, PhD, and Karl-Christian Bergmann, MD, PhD
- Subjects
Biologics ,Severe asthma ,Nasal polyps ,T2 inflammation ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Background: Severe asthma (SA) with comorbid chronic rhinosinusitis with nasal polyps (CRSwNP) is frequently associated with type 2 (T2) inflammatory endotype. Consequently, therapeutic targets are T2 biologics. The present retrospective study aimed to analyze and compare the clinical efficacy of mepolizumab, benralizumab, omalizumab, and dupilumab in patients with SA and comorbid CRSwNP. Methods: 115 adult patients with SA and CRSwNP receiving 1 of the 4 biologics (mepolizumab n = 31; benralizumab n = 27; dupilumab n = 27; omalizumab n = 30) were included in the retrospective open monocentric study. Pulmonary and rhinological parameters were evaluated by Asthma Control Test (ACT), FEV1%, GINA-severity grade, rhinological questionnaires (CRS VAS-scores and sinonasal QoL RSOM-31) before and after 4–6 months of therapy. Results: After 4–6 months of therapy, the Asthma Control Test and FEV1% significantly improved in all biologics groups (p
- Published
- 2023
- Full Text
- View/download PDF